Sinopharm

1099.HK

Beijing, China

sinopharm.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

1099.HK · Stock Price

HKD 18.73+0.33 (+1.79%)

Market Cap: $3.2B

Historical price data

Overview

Sinopharm's mission is to safeguard national health security through its comprehensive pharmaceutical ecosystem. Its achievements include developing and deploying critical COVID-19 vaccines and maintaining China's primary drug supply chain. The company's strategy leverages its state-backed, vertically integrated structure to dominate domestic distribution while expanding its proprietary biopharmaceutical portfolio in vaccines, plasma products, and traditional Chinese medicine.

Infectious DiseasesHematologyOncology Supportive CareGeneral Medicine

Technology Platform

A diversified platform encompassing inactivated and recombinant vaccine technologies, plasma fractionation for biologics, modernization of Traditional Chinese Medicine, and a nationwide digital pharmaceutical supply chain and cold-chain logistics network.

Pipeline

4 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
SPT-07A injection	Stroke, Acute	Phase 3
Human COVID-19 immunoglobulin (pH4) for intravenous injectio...	COVID-19	Phase 2
Unfractionated heparin	Primary PCI	Pre-clinical
Osmotic drugs	Stroke	Pre-clinical

Opportunities

Sinopharm is uniquely positioned to capitalize on China's aging population and the government's push for healthcare self-sufficiency.

Its massive distribution network provides a built-in commercialization channel for its growing pipeline of vaccines and biologics, while international vaccine diplomacy opens new geographic markets.

Risk Factors

The company faces significant risks from changes in Chinese government healthcare pricing and procurement policy, potential inefficiencies inherent in its vast state-owned structure, and geopolitical tensions that could limit its international expansion, particularly for its strategic vaccine business.

Competitive Landscape

Sinopharm holds a near-monopoly in pharmaceutical distribution in China, with Shanghai Pharmaceuticals as its main competitor. In biopharmaceutical R&D, it faces competition from more innovative domestic biotechs and global pharma giants, though its state-backed, integrated model provides a unique and defensible competitive moat.